5/17
09:11 am
abus
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value [Yahoo! Finance]
Low
Report
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value [Yahoo! Finance]
5/17
09:00 am
abus
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
Low
Report
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
5/7
07:30 am
abus
Arbutus to Participate in Two Upcoming Investor Conferences
Low
Report
Arbutus to Participate in Two Upcoming Investor Conferences
5/3
11:34 am
abus
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/3
09:57 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Low
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
5/3
07:00 am
abus
Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
5/2
07:45 am
abus
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update [Financial Post (Toronto, Ontario, Canada)]
5/2
07:44 am
abus
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 [Yahoo! Finance]
Low
Report
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 [Yahoo! Finance]
5/2
07:44 am
abus
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/2
07:30 am
abus
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/2
07:25 am
abus
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
Medium
Report
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
4/30
11:04 am
abus
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? [Yahoo! Finance]
4/18
07:30 am
abus
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Low
Report
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
4/4
09:06 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock.
Medium
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock.
4/4
08:36 am
abus
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna [Financial Post (Toronto, Ontario, Canada)]
4/4
08:30 am
abus
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
Low
Report
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
4/1
12:57 pm
abus
Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
Low
Report
Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
3/20
08:33 am
abus
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments [Yahoo! Finance]
Neutral
Report
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments [Yahoo! Finance]
3/8
07:52 am
abus
Arbutus to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Arbutus to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
3/8
07:30 am
abus
Arbutus to Participate in Two Upcoming Investor Conferences
Low
Report
Arbutus to Participate in Two Upcoming Investor Conferences
3/3
07:58 am
abus
Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
Low
Report
Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
3/2
07:54 am
abus
Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts [Yahoo! Finance]
Low
Report
Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts [Yahoo! Finance]
3/1
08:32 am
abus
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/1
08:13 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
3/1
08:13 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Low
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.